• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    2/13/24 5:06:22 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HRMY alert in real time by email
    SC 13G/A 1 tv01076-harmonybiosciencesho.htm SCHEDULE 13G/A harmonybiosciencesholdingsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  Harmony Biosciences Holdings Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  413197104

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  413197104

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    60,259

    7.  SOLE DISPOSITIVE POWER

    3,579,343

    8.  SHARED DISPOSITIVE POWER

    95,421

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,674,764

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.27%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Harmony Biosciences Holdings Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    630 West Germantown Pike, Suite 215
    Plymouth Meeting, PA 19462

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    413197104

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $HRMY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HRMY

    DatePrice TargetRatingAnalyst
    2/11/2025$55.00Buy
    Deutsche Bank
    12/17/2024$75.00Buy
    H.C. Wainwright
    10/10/2024Outperform
    Raymond James
    9/10/2024$56.00Buy
    UBS
    6/21/2024$48.00Buy
    Citigroup
    1/2/2024$30.00Neutral → Underperform
    BofA Securities
    9/25/2023$40.00 → $31.00Neutral → Sell
    Goldman
    9/7/2023$59.00Buy
    Berenberg
    More analyst ratings

    $HRMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Sabater Juan A.

      4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

      5/16/25 4:05:59 PM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gracias Antonio J.

      4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

      5/16/25 4:05:30 PM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Philip Ron M

      4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

      5/16/25 4:04:33 PM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRMY
    Leadership Updates

    Live Leadership Updates

    See more
    • Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

      Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics. Ron has 30 years of experience building companies, leading organizational growth, and guiding teams through the development, regulatory approval, and commercialization of novel therapies. Prior to Orbital, he was Chief Executive Officer of Spark Therapeutics, where he led the commercial launch of a novel gene therapy to treat an inherited form of blindness, expanded its therapeutic platform to larger disease areas, and acquired new technologies and assets through business developm

      4/3/25 8:05:00 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands

      Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced the appointment of Adam Zaeske as Executive Vice President and Chief Commercial Officer (CCO), effective March 31, 2025. The company's current CCO, Jeffrey Dierks, is voluntarily stepping down for personal reasons. Zaeske brings 25 years of global leadership across the pharmaceutical industry, building teams and transforming organizations in both the U.S. and Europe. He has broad functional experience spanning commercial strategy and operations, sales, marketing, market access, new product planning and finance. At Harmony, Zaeske will be responsible for leading the company's commercial organization, setting commercial strate

      3/24/25 8:05:00 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HARMONY BIOSCIENCES APPOINTS JEFFREY M. DAYNO, MD AS INTERIM CEO AND EXPANDS ROLE OF JEFF ARONIN TO EXECUTIVE CHAIRMAN

      PLYMOUTH MEETING, Pa., Jan. 6, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that John C. Jacobs is stepping down as President and Chief Executive Officer and a member of the Board of Directors to pursue another opportunity. The Harmony Board of Directors has named Jeffrey M. Dayno, MD, Harmony's Executive Vice President and Chief Medical Officer, as interim CEO effective immediately. Jeff Aronin, Harmony's founder and Board chairman, will continue to lead the Board of Directors as well as

      1/6/23 4:39:00 PM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRMY
    SEC Filings

    See more
    • SEC Form 144 filed by Harmony Biosciences Holdings Inc.

      144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

      5/16/25 4:21:54 PM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harmony Biosciences Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)

      5/15/25 4:30:15 PM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Harmony Biosciences Holdings Inc.

      10-Q - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)

      5/6/25 8:15:31 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $HRMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

      SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

      2/13/24 7:06:51 PM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

      SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

      2/13/24 5:06:22 PM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

      SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

      2/9/24 9:03:03 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on Harmony Biosciences with a new price target

      Deutsche Bank initiated coverage of Harmony Biosciences with a rating of Buy and set a new price target of $55.00

      2/11/25 7:08:06 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Harmony Biosciences with a new price target

      H.C. Wainwright initiated coverage of Harmony Biosciences with a rating of Buy and set a new price target of $75.00

      12/17/24 8:37:30 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Raymond James resumed coverage on Harmony Biosciences

      Raymond James resumed coverage of Harmony Biosciences with a rating of Outperform

      10/10/24 8:38:30 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRMY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​

      WAKIX® (pitolisant) Net Revenue of $184.7 Million for First Quarter 2025; Representing 20% Growth Year-over-Year; Reiterates Guidance of $820-$860M​ Net Income Grew 19% Year-over-Year, Building on Four Consecutive Years of Profitability; Increased Cash and Investments to Over $600 Million on Balance Sheet Completed Recruitment of Phase 3 Registrational Trial of ZYN002 in Fragile X Syndrome; On Track for Topline Data in Q3 BP1.15205, Potential Best in Class Orexin, Data to Be Presented at SLEEP 2025 Conference in June On Track for Initiation of Next-Generation Pitolisant-HD Phase 3 Registrational Trials in Narcolepsy & IH in Q4 ​Conference Call and Webcast to be Held Today at

      5/6/25 7:30:00 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025

      Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 6, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-267-6316 (domestic) or 203-518-9783 (international), and reference passcode HRMYQ125. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceu

      4/29/25 8:05:00 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome

      Data to be Presented at the Hot Topics in Child Neurology Podium Presentation Session at the American Academy of Neurology Annual Meeting Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the presentation of updated data from its Open-Label Extension (OLE) study (ZYN2-CL-017) evaluating the safety and effectiveness of ZYN002 in children, adolescents, and adults with Fragile X syndrome (FXS). The data showed clinically meaningful improvements in irritability-related symptoms prevalent in individuals with FXS. There are currently no U.S. Food & Drug Administration (FDA) approved treatments for FXS. The data will be shared during a podium presentation at the American Academy o

      4/8/25 8:05:00 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRMY
    Financials

    Live finance-specific insights

    See more
    • Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​

      WAKIX® (pitolisant) Net Revenue of $184.7 Million for First Quarter 2025; Representing 20% Growth Year-over-Year; Reiterates Guidance of $820-$860M​ Net Income Grew 19% Year-over-Year, Building on Four Consecutive Years of Profitability; Increased Cash and Investments to Over $600 Million on Balance Sheet Completed Recruitment of Phase 3 Registrational Trial of ZYN002 in Fragile X Syndrome; On Track for Topline Data in Q3 BP1.15205, Potential Best in Class Orexin, Data to Be Presented at SLEEP 2025 Conference in June On Track for Initiation of Next-Generation Pitolisant-HD Phase 3 Registrational Trials in Narcolepsy & IH in Q4 ​Conference Call and Webcast to be Held Today at

      5/6/25 7:30:00 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025

      Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 6, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-267-6316 (domestic) or 203-518-9783 (international), and reference passcode HRMYQ125. It is recommended that you dial in at least 10 minutes prior to the call. The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceu

      4/29/25 8:05:00 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs

      WAKIX® (pitolisant) Net Revenue of $201.3 Million for Fourth Quarter and $714.7 Million for Full Year 2024; Representing Growth of 23% in Year-Five on the Market 2025 WAKIX Net Revenue Guidance Between $820 - $860 Million; On Track toward a Potential $1 Billion+ Opportunity Committed to Leadership in Sleep/Wake with Next Generation Pitolisant Formulations and Orexin 2 Receptor Agonist; Phase 3 Registrational Trials with Pitolisant HD in Narcolepsy and IH to Initiate in Q4 2025 Topline Data Readout from Phase 3 Registrational Trial with ZYN002 in Fragile X Syndrome On Track for Q3 2025 Pitolisant Patent Position Strengthened with Favorable Settlement of First Generic Litigation Con

      2/25/25 7:30:00 AM ET
      $HRMY
      Biotechnology: Pharmaceutical Preparations
      Health Care